SUBSCRIBE
SUBSCRIBE

AstraZeneca

NEWS
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Peregrine Nixes Planned Trials for Bavituximab, But Hints at a Future Trial with AstraZeneca PLC’s Durvalumab
June 2, 2016
 · 
2 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Policy
Bad News for AstraZeneca PLC is Good News for Relypsa
May 27, 2016
 · 
2 min read
Pharm Country
AstraZeneca PLC Highlights Continued Progress Of Oncology Pipeline At ASCO 2016
May 19, 2016
 · 
6 min read
Job Trends
AstraZeneca PLC CEO’s Big Experiment and His Take on Keeping Employees on Edge
May 18, 2016
 · 
3 min read
Job Trends
AstraZeneca PLC Hands Out Pink Slips to Unknown Number of Contract Sales Reps
May 17, 2016
 · 
3 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
AstraZeneca PLC’s Asthma Drug Hits Phase III Goal, Predicted to Reach Market in 2017
May 17, 2016
 · 
2 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Job Trends
AstraZeneca PLC Employees from Shuttered Facility Could be Relocated to Delaware
May 9, 2016
 · 
2 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Job Trends
Delaware Employees Nervous Over AstraZeneca PLC’s $1 Billion Cost-Cutting Plans
May 3, 2016
 · 
2 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Deals
AstraZeneca PLC Stays Mum on M&A, Says “No Comment” to Medivation Bid
April 29, 2016
 · 
2 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2024 Best Places to Work
JOBS
IN THE PRESS
Press Releases
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy
June 26, 2026
 · 
10 min read
Press Releases
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
June 18, 2026
 · 
7 min read
Press Releases
AstraZeneca Joins ZERO Prostate Cancer’s Historic ‘Blitz the Barriers’ Initiative as a Founding Partner
June 15, 2026
 · 
3 min read
Press Releases
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
June 14, 2026
 · 
19 min read
Press Releases
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
June 8, 2026
 · 
7 min read
Press Releases
Leica Biosystems Announces Expansion of Collaboration to Scale Precision Medicine and Develop AI-Powered Diagnostics
June 3, 2026
 · 
4 min read
Press Releases
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones
June 1, 2026
 · 
7 min read
Press Releases
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
May 29, 2026
 · 
19 min read
Press Releases
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
May 24, 2026
 · 
19 min read
Press Releases
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
May 24, 2026
 · 
19 min read
Load More